Table 5.

Median overall survival times and survival rates relative to molecular subtypes and IPAQ categories

Molecular subtype	IPAQ	Patients	Events	Median survival time in months (95% CI)	6-month survival rate (95% CI)	12-month survival rate (95% CI)	24-month survival rate (95% CI)	36-month survival rate (95% CI)
HRpos: Luminal A-like	low	75	44	28.2 (20.9, 41.6)	0.94 (0.89, 1.00)	0.80 (0.71, 0.90)	0.55 (0.44, 0.68)	0.44 (0.33, 0.58)
	moderate	425	251	28.6 (25.1, 33.5)	0.90 (0.88, 0.93)	0.79 (0.75, 0.83)	0.56 (0.51, 0.61)	0.42 (0.38, 0.48)
	high	49	26	37.3 (30.2, NA)	0.96 (0.90, 1.00)	0.89 (0.81, 0.99)	0.69 (0.57, 0.84)	0.50 (0.37, 0.68)
HRpos: Luminal B-like	low	18	14	23.8 (11.3, NA)	0.89 (0.75, 1.00)	0.65 (0.46, 0.92)	0.47 (0.29, 0.78)	0.30 (0.14, 0.62)
	moderate	194	136	24.0 (19.9, 30.0)	0.90 (0.86, 0.95)	0.71 (0.65, 0.78)	0.49 (0.43, 0.57)	0.33 (0.26, 0.41)
	high	32	16	36.1 (24.6, NA)	0.97 (0.91, 1.00)	0.84 (0.72, 0.98)	0.71 (0.56, 0.89)	0.53 (0.38, 0.74)
HER2pos	low	26	10	39.3 (27.4, NA)	0.96 (0.89, 1.00)	0.83 (0.70, 1.00)	0.74 (0.58, 0.94)	0.56 (0.38, 0.84)
	moderate	217	105	41.0 (35.4, 51.7)	0.95 (0.92, 0.98)	0.82 (0.76, 0.87)	0.64 (0.57, 0.71)	0.54 (0.47, 0.62)
	high	35	17	40.0 (24.8, NA)	0.85 (0.74, 0.98)	0.85 (0.74, 0.98)	0.68 (0.53, 0.87)	0.51 (0.35, 0.74)
TNBC	low	11	10	9.8 (3.2, NA)	0.54 (0.31, 0.93)	0.36 (0.16, 0.79)	0.18 (0.05, 0.63)	NA
	moderate	104	79	13.0 (10.8, 18.2)	0.80 (0.72, 0.88)	0.54 (0.45, 0.65)	0.30 (0.22, 0.41)	NA
	high	20	15	15.0 (10.6, NA)	0.94 (0.83, 1.00)	0.61 (0.43, 0.88)	0.20 (0.07, 0.52)	NA

HER2pos Human epidermal growth factor receptor 2 positive, HRpos Hormone receptor-positive, TNBC Triple negative breast cancer, IPAQ International Physical Activity Questionnaire, CI Confidence interval, NA Not applicable – could not be calculated